WO1995022600A1 - Therapie ribozymique de l'infection par le virus de l'hepatite b - Google Patents

Therapie ribozymique de l'infection par le virus de l'hepatite b Download PDF

Info

Publication number
WO1995022600A1
WO1995022600A1 PCT/US1995/002149 US9502149W WO9522600A1 WO 1995022600 A1 WO1995022600 A1 WO 1995022600A1 US 9502149 W US9502149 W US 9502149W WO 9522600 A1 WO9522600 A1 WO 9522600A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
ribozyme
hbv
dna
vector
Prior art date
Application number
PCT/US1995/002149
Other languages
English (en)
Inventor
Tsvi Goldenberg
Original Assignee
Immusol, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol, Inc. filed Critical Immusol, Inc.
Priority to AU19252/95A priority Critical patent/AU1925295A/en
Publication of WO1995022600A1 publication Critical patent/WO1995022600A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Abstract

L'invention concerne des ribozymes utiles pour traiter ou prévenir l'infection par le virus de l'hépatite B (VHB) dans un organisme ou chez un sujet, ainsi que des méthodes de traitement d'une infection à VHB. Des réactifs tels que des vecteurs, des cellules hôtes, des molécules d'ADN codant pour ces ribozymes utiles dans des méthodes de traitement et de prévention de l'infection à VHB sont également décrits.
PCT/US1995/002149 1994-02-22 1995-02-21 Therapie ribozymique de l'infection par le virus de l'hepatite b WO1995022600A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19252/95A AU1925295A (en) 1994-02-22 1995-02-21 Ribozyme therapy for hepatitis b infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20080694A 1994-02-22 1994-02-22
US08/200,806 1994-02-22

Publications (1)

Publication Number Publication Date
WO1995022600A1 true WO1995022600A1 (fr) 1995-08-24

Family

ID=22743277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/002149 WO1995022600A1 (fr) 1994-02-22 1995-02-21 Therapie ribozymique de l'infection par le virus de l'hepatite b

Country Status (2)

Country Link
AU (1) AU1925295A (fr)
WO (1) WO1995022600A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008309A2 (fr) * 1995-08-29 1997-03-06 Immusol, Inc. Therapie utilisant de ribozymes contre les infections a virus de l'hepatite b
EP2042510A3 (fr) * 2002-02-20 2009-06-24 Sirna Therapeutics Inc. Inhibition au moyen d'interférence ARN d'une expression de gène utilisant un acide nucléique à petit interférent modifié chimiquement (siNA)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ADV. EXP. MED. BIOL., Volume 312, issued 1992, HSIEH et al., "Delta Virus as a Vector for the Delivery of Biologically-active RNAs: Possibly a Ribozyme Specific for Chronic Hepatitis B Virus Infection", pages 125-128; & MEDLINE No.: 08246095, 92384095. *
ANTIVIRAL RES., Volume 20, Supplemental 1, issued 1993, BOCKMAN et al., "External Guide Sequences (EGS) Elicit Cleavage of Hepatitis B Virus RNA by RNase P", page 146, Abstract No. 191. *
ANTIVIRAL RES., Volume 20, Supplemental 1, issued 1993, GEORGE et al., "Ribozyme Mediated Cleavage of Hepatitis B Virus Surface Antigen mRNA", page 165, Abstract No. 227. *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH AND COMMUNICATIONS, Volume 189, Number 2, issued 15 December 1992, WEIZSACKER et al., "Cleavage of Hepatitis B Virus RNA by Three Ribozymes Transcribed from a Single DNA Template", pages 743-748. *
CHEMICAL ABSTRACTS, Volume 117, Number 1, issued 1991, WANG et al., "Secondary Structure of a Hepatitis B Surface Antigen Gene mRNA-specific Ribozyme as Determined by Scanning Tunnelling Microscopy", Acc. No. 3250; & BINGDU XUEBAO, 7(4), pages 369-371. *
CHEMICAL ABSTRACTS, Volume 120, Number 7, issued 1993, ZHU et al., "Ribozyme that Cleave Site-specifically the RNA Fragment Derived from Core Antigen Gene of Hepatitis B Virus in Vitro", Acc. No. 72401; & SHENGWU HUAXUE YU SHENGU WULI XUEBO, 25(3), pages 313-317. *
CHEMICAL ABSTRACTS, Volume 121, Number 23, issued 1993, WANG et al., "Effect of Ribozyme (Ripc) on HBV in Vitro", Acc. No. 275039; & BINGDU XUEBAO, 9(3), pages 278-280. *
FASEB J., Volume 7, Number 7, issued 1993, WANG et al., "Effects of Ribozyme on HBV In-Vitro and in HEPG2 Cells", page A1301, Abstract No. 1447. *
HEPATOLOGY, Volume 16, No. 4, Part 2, issued October 1992, WEIZSAECKER et al., "Ribozyme Mediated Cleavage of Hepatitis B and Duck Hepatitis B Virus RNA", page 88A, Abstract No. 175. *
J. CELL. BIOCHEM., Suppl. 0, Volume 17, issued 1993, NARAYAN et al., "Nuclease Resistant Ribozymes Against Hepatitis B Surface Antigen mRNA", page 213, Abstract No. S411. *
J. CELL. BIOCHEM., Suppl. 0, Volume 17, issued 1993, TAKLE et al., "Delivery of Stable Ribozymes to Virally-infected Cells", page 209, Abstract No. S317. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008309A2 (fr) * 1995-08-29 1997-03-06 Immusol, Inc. Therapie utilisant de ribozymes contre les infections a virus de l'hepatite b
WO1997008309A3 (fr) * 1995-08-29 1997-07-10 Immusol Inc Therapie utilisant de ribozymes contre les infections a virus de l'hepatite b
EP2042510A3 (fr) * 2002-02-20 2009-06-24 Sirna Therapeutics Inc. Inhibition au moyen d'interférence ARN d'une expression de gène utilisant un acide nucléique à petit interférent modifié chimiquement (siNA)

Also Published As

Publication number Publication date
AU1925295A (en) 1995-09-04

Similar Documents

Publication Publication Date Title
US6043077A (en) Hepatitis C virus ribozymes
JP4330797B2 (ja) Ｃｃｒ５受容体の発現を阻害することが可能なリボザイム
US6114167A (en) Ribozymes targeting the MoMLV PSI packaging sequence and the HIV tat sequence
Birikh et al. The structure, function and application of the hammerhead ribozyme
AU702373B2 (en) Stabilized external guide sequences
US6057153A (en) Stabilized external guide sequences
US6107027A (en) Ribozymes for treating hepatitis C
US20040248296A1 (en) HIV therapeutic
WO1995031552A2 (fr) Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'epingle a cheveux
CA2261023A1 (fr) Nouvelles molecules d'arn catalytique
Rossi Therapeutic antisense and ribozymes
EP1298208A2 (fr) Ribozymes contre une séquence de Tat de HIV
WO2000032765A9 (fr) Ribozymotherapie destinee au traitement et/ou a la prevention de la restenose
US5834440A (en) Ribozyme therapy for the inhibition of restenosis
WO1995022600A1 (fr) Therapie ribozymique de l'infection par le virus de l'hepatite b
AU703964B2 (en) Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
Rossi Therapeutic ribozymes: principles and applications
AU757034B2 (en) Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
WO1997008309A2 (fr) Therapie utilisant de ribozymes contre les infections a virus de l'hepatite b
WO1997008309A9 (fr) Therapie utilisant de ribozymes contre les infections a virus de l'hepatite b
US20020013458A1 (en) Enzymatic nucleic acid treatment of disases or conditions related to hepatitis c virus infection
CA2578402A1 (fr) Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'e ingle a cheveux
AU2588795A (en) Human papilloma virus inhibition by a hairpin ribozyme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA